Clinical trials & evidence

China’s Biliary-Cancer Bet Has a Global Access Problem

Alzheimer’s Trials Are Finally Blood-Gated

GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up

ALS Needs Proof, Not Just Another Biomarker

The Transplant Is Not the Finish Line

For Pompe Infants, Time Is the Comparator

Alzheimer’s Trials Still Measure Too Little, Too Late

Corxel’s oral GLP-1 trial adds momentum. The real question is who these drugs will reach

Deep learning uncovers a new ECG biomarker for sudden cardiac death
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
